ALK and non-small cell lung carcinoma: In the past several decades, platinum-based doublet regimens are the mainstay of chemotherapy in patients with advanced nonsmall-cell lung cancer (NSCLC).1 Nevertheless, somatic mutations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and K-Ras are widely found in NSCLC.